Save Product
Product Details
Specificity
Specifically recognizes the DXd and DXd structurally similar molecules.
Source
Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) is a Rabbit monoclonal antibody recombinantly expressed from HEK293 cells.
Clone
M1B09
Isotype
Rabbit IgG | Rabbit Kappa
Conjugate
Unconjugated
Immunogen
DXD-BSA
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) at 5 μg/mL, add Trastuzumab Deruxtecan in the 100% Human Serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) at 5 μg/mL, add Trastuzumab Deruxtecan in the 0.5% BSA and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Protocol
Serial dilutions of DXD were added into Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290): Trastuzumab Deruxtecan binding reactions. The half maximal inhibitory concentration (IC50) is 0.05452 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) with Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF conjugated antibody respectively.
The coating antibody was Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Disitamab Vedotin (RC48), Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was HRP conjugated Anti-Human-IgG-Fc Antibody (6F11C8), mAb (Acro, Cat. No. IGG-LY69) used at 1:10000 concentration.
Monoclonal Anti-DXD & Exatecan Antibody, Rabbit IgG (M1B09) (Cat. No. DXD-MY2290) is specific to Trastuzumab Deruxtecan, and has no cross-reactivity with Disitamab Vedotin (RC48), Sacituzumab Govitecam, Trastuzumab MMAE, Doxorubicin-ADC and IgG1-MMAF (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing